A Phase I Multicenter Study To Assess The Safety, Tolerability, And Immunogenicity Of Mrna-4157 Alone In Patients With Resected Solid Tumors And In Combination With Pembrolizumab In Patients With Unresectable Solid Tumors.

JOURNAL OF CLINICAL ONCOLOGY(2019)

引用 71|浏览42
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要